This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waeber, B. Articles by Gavras, H. Search for Related Content PubMed PubMed Citation Articles by Waeber, B. Articles by Gavras, H.

Hypertension, Vol 2, 236-242, Copyright © 1980 by American Heart Association

ARTICLES

Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril

B Waeber, HR Brunner, DB Brunner, AL Curtet, GA Turini and H Gavras

Captopril, an inhibitor of angiotensin converting enzyme, was administered twice daily to 13 hypertensive patients for a mean period of 9 weeks. Continuous blood pressure control in the ambulatory patients was established with a portable blood pressure recorder. Notwithstanding, in eight patients with normal renal function, plasma converting enzyme was found to resume normal activity before administration of the morning dose of captopril. Only in 5 patients with impaired renal function did some blockade of plasma converting enzyme persist for more than 12 hours. Measured plasma converting enzyme activity seemed to reflect total conversion of angiotensin I, including conversion in the pulmonary vascular bed, since changes in its activity were closely paralled by changes in plasma aldosterone levels. Bradykinin accumulation seems unlikely when converting enzyme and thus, presumably, kininase II has resumed normal activity. Captopril administration does not seem to alter plasma epinephrine or norepinephrine levels. Blood pressure reduction in the face of normal angiotensin converting enzyme activity is probably due to hyporesponsiveness of the arterioles to pressor hormones, which may be due to specific renin-related and/or nonspecific effects of captopril.

This article has been cited by other articles:

				R. M.A. van de Wal, D. J. van Veldhuisen, W. H. van Gilst, and A. A. Voors Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur. Heart J., November 2, 2005; 26(22): 2361 - 2367. [Abstract] [Full Text] [PDF]

				A. Forclaz, M. Maillard, J. Nussberger, H. R. Brunner, and M. Burnier Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor? Hypertension, January 1, 2003; 41(1): 31 - 36. [Abstract] [Full Text] [PDF]

				S. Laurent, P. Boutouyrie, M. Azizi, C. Marie, C. Gros, J.-C. Schwartz, J.-M. Lecomte, and J. Bralet Antihypertensive Effects of Fasidotril, a Dual Inhibitor of Neprilysin and Angiotensin-Converting Enzyme, in Rats and Humans Hypertension, May 1, 2000; 35(5): 1148 - 1153. [Abstract] [Full Text] [PDF]

				N. J. Brown and D. E. Vaughan Angiotensin-Converting Enzyme Inhibitors Circulation, April 14, 1998; 97(14): 1411 - 1420. [Abstract] [Full Text] [PDF]

				B. Waeber, H. R. Brunner, P. Burckhardt, and H. Gavras Hypertension in a Patient With Hypercalcemia: Captopril and Verapamil Arch Intern Med, January 1, 1982; 142(1): 143 - 145. [Abstract] [PDF]